NIH VideoCast - Defective lysosomal transport in Parkinson’s disease impairs polyamine and lipid homeostasis

Skip Navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Defective lysosomal transport in Parkinson’s disease impairs polyamine and lipid homeostasis

Loading... Loading video...

339 Views

Air date:	Monday, April 10, 2023, 12:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 339 (128 Live, 211 On-demand)
Category:	Neuroscience
Runtime:	01:09:12
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Neuroscience Series Seminar The core business of the Lab of Cellular Transport Systems (LCTS), headed by Prof. Dr. Peter Vangheluwe, is the understanding of which unique molecular properties define a specific P-type ATPase and unraveling its physiological role in health and disease. P2 ATPases - ION TRANSPORTERS LCTS built a strong track record in the research area of the P2-type ATPases, the primary cellular Ca2+ transporters. More specifically, the lab contributed to important discoveries on the structure-function relationship and physiological role of the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pumps and the secretory pathway Ca2+- ATPase (SPCA) isoforms. P4 ATPases - ATP10B Parkinson’s disease (PD) is a progressive neurodegenerative brain disease presenting with a variety of motor and non-motor symptoms, loss of midbrain dopaminergic neurons in the substantia nigra pars compacta and the occurrence of α-synucleinpositive Lewy bodies in surviving neurons. Together with the Christine Van Broeckhoven lab we identified compound heterozygous mutations in the P4 transport ATPase class V type 10B gene (ATP10B) in 3 Early Onset PD patients. Our lab successfully established that ATP10B, previously uncharacterized, encodes a late endo-lysosomal GluCer and phosphatidylcholine (PC) lipid fippase in which patient associated compound heterozygous mutations impair functional activities of ATP10B. P5 ATPases - Discovery of the mammalian polyamine transporters Phylogenetic analysis of P-type ATPase sequences in early genomic sequences revealed the existence of a fifth P-type ATPase subfamily, which is exclusively found in eukaryotic lineages. However, the substrate specificity and exact cellular role of the P5-type ATPases remained elusive for a long time. Several of the five human P5 ATPases have attracted considerable interest as they are implicated in human disorders. Pioneering work of our lab successfully revealed the molecular identity of ATP13A2, a P5B-ATPase, as the first identified mammalian polyamine transporter. ATP13A2 is genetically implicated in a spectrum of neurodegenerative disorders such as Kufor-Rakeb syndrome, early-onset Parkinson’s disease (PD) but also NCL and ALS. Importantly, our work demonstrates that defective lysosomal polyamine export represents a novel pathway in the molecular pathogenesis of lysosome-dependent cell death in neurodegeneration. LCTS currently has several follow-up projects running on ATP13A2, including a drug discovery program. Other P5B-ATPase isoforms are also under study, such as ATP13A3 in pulmonary arterial hypertension and ATP13A4 in neurodevelopment disorders. For more information go to https://research.ninds.nih.gov/neuroscience-seminar-series

NLM Title:	Defective lysosomal transport in Parkinson's disease impairs polyamine and lipid homeostasis / Peter Vangheluwe.
Author:	Vangheluwe, Peter. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): NIH Neuroscience Series Seminar The core business of the Lab of Cellular Transport Systems (LCTS), headed by Prof. Dr. Peter Vangheluwe, is the understanding of which unique molecular properties define a specific P-type ATPase and unraveling its physiological role in health and disease. P2 ATPases - ION TRANSPORTERS LCTS built a strong track record in the research area of the P2-type ATPases, the primary cellular Ca2+ transporters. More specifically, the lab contributed to important discoveries on the structure-function relationship and physiological role of the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pumps and the secretory pathway Ca2+- ATPase (SPCA) isoforms. P4 ATPases - ATP10B Parkinson"s disease (PD) is a progressive neurodegenerative brain disease presenting with a variety of motor and non-motor symptoms, loss of midbrain dopaminergic neurons in the substantia nigra pars compacta and the occurrence of α-synucleinpositive Lewy bodies in surviving neurons. Together with the Christine Van Broeckhoven lab we identified compound heterozygous mutations in the P4 transport ATPase class V type 10B gene (ATP10B) in 3 Early Onset PD patients. Our lab successfully established that ATP10B, previously uncharacterized, encodes a late endo-lysosomal GluCer and phosphatidylcholine (PC) lipid fippase in which patient associated compound heterozygous mutations impair functional activities of ATP10B. P5 ATPases - Discovery of the mammalian polyamine transporters Phylogenetic analysis of P-type ATPase sequences in early genomic sequences revealed the existence of a fifth P-type ATPase subfamily, which is exclusively found in eukaryotic lineages. However, the substrate specificity and exact cellular role of the P5-type ATPases remained elusive for a long time. Several of the five human P5 ATPases have attracted considerable interest as they are implicated in human disorders. Pioneering work of our lab successfully revealed the molecular identity of ATP13A2, a P5B-ATPase, as the first identified mammalian polyamine transporter. ATP13A2 is genetically implicated in a spectrum of neurodegenerative disorders such as Kufor-Rakeb syndrome, early-onset Parkinson"s disease (PD) but also NCL and ALS. Importantly, our work demonstrates that defective lysosomal polyamine export represents a novel pathway in the molecular pathogenesis of lysosome-dependent cell death in neurodegeneration. LCTS currently has several follow-up projects running on ATP13A2, including a drug discovery program. Other P5B-ATPase isoforms are also under study, such as ATP13A3 in pulmonary arterial hypertension and ATP13A4 in neurodevelopment disorders. For more information go to https://research.ninds.nih.gov/neuroscience-seminar-series.
Subjects:	Lysosomal Storage Diseases, Nervous System--complications Lysosomes--metabolism Parkinson Disease--etiology Parkinson Disease--genetics Polyamines--antagonists & inhibitors Proton-Translocating ATPases--genetics
Publication Types:	Lecture Webcast

NLM Classification:	WL 359
NLM ID:	9918592677306676
CIT Live ID:	49480
Permanent link:	https://videocast.nih.gov/watch=49480

Related Videos...